Dr. Christian Gisselbrecht on Defining Refractory Disease in DLBCL

Christian Gisselbrecht, MD
Published: Saturday, Jun 11, 2016



Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
 
Instead of just assuming a patient is refractory because they’ve relapsed, Gisselbrecht’s team wanted a more precise definition.
 
In collaboration with several companies and cancer centers, Gisselbrecht’s team determined several types of refractory patients.
 
By defining different groups of relapsed patients, prognostic factors can be determined for specific populations, says Gisselbrecht.

<<< View more from the 2016 EHA Congress


Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).
 
Instead of just assuming a patient is refractory because they’ve relapsed, Gisselbrecht’s team wanted a more precise definition.
 
In collaboration with several companies and cancer centers, Gisselbrecht’s team determined several types of refractory patients.
 
By defining different groups of relapsed patients, prognostic factors can be determined for specific populations, says Gisselbrecht.

<<< View more from the 2016 EHA Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x